Clinical trials: To Evaluate the Rate of Digestive and Urinary Toxicity
To Evaluate the Rate of Digestive and Urinary Toxicity
Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk
The standard treatment of high-risk prostatic adenocarcinoma is based on pelvic-prostatic external radiotherapy combined with concomitant and adjunctive hormone therapy for a total of 3 years.
- Trial name
- SHORT (NCT03417336)
- Testing
- prostatic boost in brachytherapy with high dose rate (HDR)
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Georges Francois Leclerc